CASE REPORT
A case of concomitant juvenile idiopathic arthritis (JIA) and paediatric-onset multiple sclerosis (POMS) – treatment with secukinumab and dimethyl fumarate followed by ofatumumab
1
Department of Neurology Medical University, Lublin, Poland
Corresponding author
Aleksandra Jartych
Department of Neurology, Medical University, Jaczewskiego 8, 20-954 Lublin, Poland
Department of Neurology, Medical University, Jaczewskiego 8, 20-954 Lublin, Poland
J Pre Clin Clin Res. 2024;1(18):16-20
KEYWORDS
juvenile idiopathic arthritisautoimmune diseasesofatumumabdimethyl fumaratemultiple sclerosissecucinumab
TOPICS
ABSTRACT
The aim of this case report is to highlight new possible treatment methods for concomitant juvenile idiopathic arthritis and
multiple sclerosis in young patients. Promising results of using ofatumumab, secukinumab and dimethyl fumarate, both in
the clinical case of a 22-year-old patient and mentioned literature, allows the belief that there is a chance for improving the
quality of life of those who suffer from coexisting autoimmune diseases. However, it is crucial to perform further research in
terms of the necessity and safety of the mentioned therapies, especially in the paediatric population, among whom there
often exists difficulty in using treatment not registered for under-aged patients. Furthermore, the higher risk of side-effects
caused by combined treatment of two autoimmune diseases should also be taken into consideration.
Jartych A, Jamróz-Wiśniewska A, Rejdak K, Kleszczyńska W, Kaczor M. A case of concomitant juvenile idiopathic arthritis (JIA) and paediatric-
onset multiple sclerosis (POMS) – treatment with secukinumab and dimethyl fumarate followed by ofatumumab. J Pre-Clin Clin Res.
2024; 18(1): 16–20. doi: 10.26444/jpccr/185685
REFERENCES (25)
1.
Landry RL, Embers ME. The Probable Infectious Origin of Multiple Sclerosis. NeuroSci. 2023;4(3):211–234. https://doi.org/10.3390/neuros....
2.
Hennet T, Borsig L. Breastfed at Tiffany’s. Trends Biochem Sci. 2016;41(6):508–518. https://doi.org/10.1016/j.tibs....
3.
De Silvestri A, Capittini C, Mallucci G, et al. The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. Dis Markers. 2019;2019:1409069. https://doi.org/10.1155/2019/1....
4.
Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15(9):931–934. https://doi.org/10.1016/j.autr....
5.
Brenton JN, Kammeyer R, Gluck L, et al. Multiple Sclerosis in Children: Current and Emerging Concepts. Semin Neurol. 2020;40(2):192–200. https://doi.org/10.1055/s-0040....
6.
Jakimovski D, Awan S, Eckert SP, et al. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs. 2022;36(1):45–59. https://doi.org/10.1007/s40263....
7.
Steinborn B. Stwardnienie rozsiane w wieku rozwojowym. In: Losy J, editor. Stwardnienie rozsiane. 2nd ed. Lublin; 2019. p. 233–255. Polish.
8.
Chighizola CB, Ferrito M, Marelli L, et al. Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review. Biomedicines. 2022;10(8):2041. https://doi.org/10.3390/biomed....
9.
Coşkun AN, Günbey C, Göçmen R, et al. Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. Mult Scler Relat Disord. 2019;27:20–22. https://doi.org/10.1016/j.msar....
10.
Puszczewicz MJ, Tuchocka-Piotrowska A, Majewski D, et al. Przypadek współwystępowania młodzieńczego idiopatycznego zapalenia stawów i stwardnienia rozsianego. Ann Acad Med Stetin. 2006;52 Suppl 2:85–88. Polish.
11.
Krawiec P, Batko B. Zastosowanie sekukinumabu w leczeniu pacjentów z łuszczycowym zapaleniem stawów i chorobami współistniejącymi. Forum Reumatol 2020;6(2):85–90. https://doi.org/10.5603/FR.202....
12.
Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582–590. https://doi.org/10.1136/annrhe....
13.
Blair HA. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2021;81(4):483–494. Erratum in: Drugs. 2021;81(6):735. https://doi.org/10.1007/s40265....
14.
Eshwar V, Kamath A, Shastry R, et al. A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. Pharmaceuticals (Basel). 2022;15(11):1365. https://doi.org/10.3390/ph1511....
15.
Vermersch P, Scaramozza M, Levin S, et al. Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial. JAMA Netw Open. 2022;5(9):e2230439. https://doi.org/10.1001/jamane....
16.
Saidu NEB, Kavian N, Leroy K, et al. Dimethyl fumarate, a two-edged drug: Current status and future directions. Med Res Rev. 2019;39(5):1923–1952. https://doi.org/10.1002/med.21....
17.
Dello Russo C, Scott KA, Pirmohamed M. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature. Pharmacol Ther. 2021;219:107710. https://doi.org/10.1016/j.phar....
18.
Liang G, Chai J, Ng HS, et al. Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2020;46:102566. https://doi.org/10.1016/j.msar....
19.
Di Tullio F, Odorici G, Lasagni C, et al. Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis. Dermatol Ther. 2020;33(6):e13943. https://doi.org/10.1111/dth.13....
20.
Vitale C, Falchi L, Ciccone M, et al. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. 2020;11(1):19–23. https://doi.org/10.1016/j.jgo.....
21.
Bar-Or A, Wiendl H, Montalban X, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022;28(6):910–924. https://doi.org/10.1177/135245....
22.
Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546–557. https://doi.org/10.1056/NEJMoa....
23.
Kang C, Blair HA. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis. Drugs. 2022;82(1):55–62. Erratum in Drugs. 2022;82(1):63. https://doi.org/10.1007/s40265....
24.
Novartis Pharmaceuticals Corporation. KESIMPTA® (ofatumumab) injection, for subcutaneous use: US prescribing information. https://www.hcp.novartis.com/p.... (accessed 2021.11.16).
25.
Zaripova LN, Midgley A, Christmas SE, et al. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135. https://doi.org/10.1186/s12969....
| eISSN: | 1898-7516 |
| ISSN: | 1898-2395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
